BELotaxel(Docetaxel) and bellOXa(Oxaliplatin) in Advanced NSCLC

Inclusion Criteria: * Stage IIIB/IV or Relapsed NSCLC * Age \>= 18 years * At least one measurable lesion by RECIST (version 1.1) * ECOG PS 0, 1, 2 * Hematologic profile * Hgb \> 8 g/dL, ANC \>= 2,000/m3, Platelet \>= 100,000/m3 * Hepatic profile * Total bilirubin \<= 1.5 x upper normal value * Transaminases \<= 3 x upper normal value \<= 5 x upper normal value in case of liver metastasis * Creatinine \<= 1.5mg/dL * Patients should be recovered from toxicities of previous treatment. * Written informed consent by patient or surrogates Exclusion Criteria: * Patients who had been previously treated with chemotherapy for NSCLC * Active infection requiring antibiotics treatment * Prior diagnosis of other malignancy except radically treated basal cell or squamous cell carcinoma of the skin and carcinoma in situ of the uterine cervix * Peripheral neuropathy \>= grade 2 by NCI CTCAE 4.0 * Uncontrolled hypertension, Acute myocardial infarction within 6 months Unstable angina, Congestive heart failure \>= NYHA grade 2 Uncontrolled significant arrhythmia * Patients who entered other clinical trials within 4 weeks * Pregnant or lactating women. women with child bearing age who are not willing to a contraceptive measure